Table 1.
Patients’ characteristics
| Non antibiotic exposure (n=97) |
Antibiotic exposure (n=43) |
P-value | Total (N=140) | |
|---|---|---|---|---|
| Age | ||||
| Mean (SD) | 65.5 (7.35) | 65.9 (9.79) | 0.61 | 65.7 (8.15) |
| Median [Q1, Q3] | 65.8 [60.0, 71.0] | 65.1 [60.9, 73.5] | 65.5 [60.2, 71.8] | |
| Sex | ||||
| Men | 70 (72.2%) | 27 (62.8%) | 0.322 | 97 (69.3%) |
| Women | 27 (27.8%) | 16 (37.2%) | 43 (30.7%) | |
| Histology | ||||
| Adenocarcinoma | 71 (73.2%) | 23 (53.5%) | 0.013 | 94 (67.1%) |
| Squamous | 10 (10.3%) | 13 (30.2%) | 23 (16.4%) | |
| Others | 16 (16.5%) | 7 (16.3%) | 23 (16.4%) | |
| Stage | ||||
| IIIa | 1 (1.03%) | 1 (2.33%) | 0.622 | 2 (1.43%) |
| IIIb | 7 (7.22%) | 2 (4.65%) | 9 (6.43%) | |
| IV | 89 (91.8%) | 40 (93.0%) | 129 (92.1%) | |
| Drug | ||||
| Atezolizumab | 38 (39.2%) | 11 (25.6%) | 0.238 | 49 (35.0%) |
| Nivolumab | 18 (18.6%) | 12 (27.9%) | 30 (21.4%) | |
| Pembrolizumab | 41 (42.3%) | 20 (46.5%) | 61 (43.6%) | |
| ECOG | ||||
| 0 | 30 (30.9%) | 8 (18.6%) | 0.11 | 38 (27.1%) |
| 1 | 67 (69.1%) | 34 (79.1%) | 101 (72.1%) | |
| 2 | 0 (0%) | 1 (2.33%) | 1 (0.714%) | |
| Smoker | ||||
| Previous | 55 (56.7%) | 21 (48.8%) | 0.658 | 76 (54.3%) |
| Never | 5 (5.15%) | 3 (6.98%) | 8 (5.71%) | |
| Current | 37 (38.1%) | 19 (44.2%) | 56 (40.0%) | |
| PDL1 expression | ||||
| PDL1 ≥50 | 38 (39.1%) | 21 (48.8%) | 0.146 | 59 (42.1%) |
| PDL1 < 50 | 43 (44.3%) | 13 (30.2%) | 56 (40.0%) | |
ECOG: Eastern Cooperative Oncology Group